 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Studies Make Case for High-Res MS as Triple Quad Alternative, Though Questions and Challenges Loom
October 12, 2012
Studies Make Case for High-Res MS as Triple Quad Alternative, Though Questions and Challenges Loom
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- At JP Morgan Mass Spec Vendors Highlight Clinical Efforts, Performance of High-Profile Releases
January 11, 2013 / ProteoMonitor - Targeted Mass Spec Slowly but Steadily Moving Toward Broader Commercial, Clinical Adoption
September 21, 2012 / ProteoMonitor - Mass Spec Informatics and Applications Take Center Stage at ASMS 2012
May 25, 2012 / ProteoMonitor - 2012 Sees Rise of Targeted Proteomics and DIA-MS, Continued Clinical Push by Big Industry Players
January 4, 2013 / ProteoMonitor - BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
June 8, 2012 / ProteoMonitor